Drug Type Prophylactic vaccine, mRNA vaccine |
Synonyms COVID-19 messenger ribonucleic acid(mRNA) vaccine from Stemirna Therapeutics, COVID-19-mRNA Vaccine(Stemirna Therapeutics), SARS-Cov-2 mRNA vaccine immunization(Stemirna Therapeutics) + [4] |
Target |
Action inhibitors |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Laos (08 Dec 2022), |
RegulationEmergency Use Authorization (Laos) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | Laos | 08 Dec 2022 |
Phase 3 | - | SW-BIC-213 (mRNA vaccine) | gaptcqbzos(oorsjeyvcn) = All adverse reactions observed during the study were tolerable, transient, and resolved spontaneously. Solicited local reactions were the main adverse reactions in both the SW-BIC-213 group (43.8%) and BBIBP group (14.8%) hxccwiddvd (ytuaosxpvq ) | Positive | 01 Jan 2024 | ||
BBIBP (inactivated vaccine) | |||||||
Not Applicable | Multiple Sclerosis anti-CD20 therapy | sphingosine-1-phosphate receptor modulators (S1PM) | 5,545 | (People with multiple sclerosis (pwMS)) | rqvmxlbszb(fpoecazgnx) = kparuapwua xtljkosdjy (mrvdvodbpi ) View more | Positive | 01 Oct 2023 | |
Anti-CD20 therapy | rqvmxlbszb(fpoecazgnx) = pclthsbhao xtljkosdjy (mrvdvodbpi ) |